IMUNON, Inc., a clinical-stage biotechnology company based in Lawrenceville, N.J., reported final Phase II data from the OVATION 2 trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy in 112 women with newly diagnosed advanced ovarian cancer. According to the company's announcement, the final analysis showed a median overall survival of 45.1 months in the IMNN-001 arm compared to 30.4 months with chemotherapy alone, a difference of 14.7 months. This figure widened from an earlier interim analysis that reported an 11.1-month median OS difference (40.5 vs. 29.4 months). The company also reported that patients who received PARP inhibitors as maintenance therapy in addition to IMNN-001 and chemotherapy achieved a median OS of 65.6 months versus 41.4 months for chemotherapy alone, a 24.2-month difference.
The OVATION 2 trial was an open-label, randomized study in which 112 patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer were assigned 1:1 to receive IMNN-001 (up to 17 weekly intraperitoneal doses at 100 mg/m²) plus carboplatin and paclitaxel, or chemotherapy alone. The company described the safety profile as favorable but did not disclose numerical safety data, adverse event rates, or discontinuation figures. As a Phase II study, the trial was not powered for statistical significance. The PARP inhibitor subgroup analysis was not prespecified as a primary comparison, and the company did not report the number of patients in each subgroup, confidence intervals, or p-values for any of the OS comparisons. The data are from a completed but modestly sized open-label trial, and the absence of blinding introduces potential confounders in outcome assessment.
IMNN-001 is a non-viral DNA-based immunotherapy designed to enable local production of interleukin-12 in the peritoneal cavity. In the standard first-line setting, carboplatin plus paclitaxel yields median progression-free survival of approximately 16 to 18 months, while the addition of bevacizumab to that regimen has extended median PFS by roughly four months in prior trials. Cross-trial comparisons are limited by differences in study design, duration, and patient populations. IMUNON said its Phase III OVATION 3 trial, which uses OS as the primary endpoint in a larger cohort of approximately 500 patients, is enrolling ahead of plan.
Spot something wrong? Report an issue with this article